Date | Price Target | Rating | Analyst |
---|---|---|---|
6/13/2024 | $28.00 | Outperform | Robert W. Baird |
6/6/2024 | $22.00 | Buy | H.C. Wainwright |
11/28/2023 | $20.00 | Overweight | JP Morgan |
11/28/2023 | $20.00 | Buy | Stifel |
11/28/2023 | $19.00 | Outperform | Leerink Partners |
11/28/2023 | $22.00 | Outperform | RBC Capital Mkts |
11/28/2023 | $23.00 | Buy | Chardan Capital Markets |
Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00
H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00
JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $22 price target.
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET Chardan's 8th Annual Genetic
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness and troponin I, in majority of participants at 12 months Increased post-treatment frataxin expression above baseline in all participants evaluated via myocardial biopsy to date LX2006 was well tolerated with no treatment-related serious adverse events to date; proceeding to Cohort 3 in SUNRISE-FA, with one
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)